

Date

Pancreatitis

Pancreatitis

NICE guideline NG104

Declarations of interest

September 2018

For internal NGC and NICE use

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© National Guideline Centre, 2018

Contents

1	Declarations of interest	5
----------	---------------------------------------	----------

1 Declarations of interest

The September 2014 version of the NICE code of practice for declaring and dealing with conflicts of interest policy was applied to this guideline.

Richard Charnley (chair)

Committee meeting	Declaration of interest	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Alex Horton (radiologist)

Meeting	Declaration	Classification	Action taken
Initial application	Local radiologist for the following trials: Epock and STOP HCC, both commercial trials funded by BTG UK. TACE2 trial: Closed prior to recruitment at local site. Sillajen (PHOCUS) study: Funded by Sillajen, San Francisco, USA	Non-specific non-personal non-financial	Declare and participate
GC 01	None	-	-
GC 02	HCC Round table meeting in London 22/3/16. Paid honorarium by Bayer. Not related to pancreatitis	Non-specific Personal Financial	Withdraw from the nutritional intervention protocol discussions because it was initially thought to be Specific personal financial classification. Bayer previously

Meeting	Declaration	Classification	Action taken
			involved in enzyme replacement therapy. However, have not been involved with this for some time. ^a
	BTG Rep training event DC Beads in TACE 5/3/15. Paid attendance. (entry left in register as in GC minutes on NICE website)	Non-specific Personal Financial (item over 1 year old)	Declare and Participate
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	HCC round table meeting in London, April 2017. Paid honorarium by Bayer. Not related to pancreatitis	Non-specific Personal Financial	Withdraw from the nutritional intervention protocol discussions because it was initially thought to be Specific personal financial classification. Bayer previously involved in enzyme replacement therapy. However, have not been involved with this for some time. ^b
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-

^a Later found to not be a conflict.

^b Later found to not be a conflict.

Meeting	Declaration	Classification	Action taken
GC13	None	-	-

Amy Lucas (lay member)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	Liverpool patient group member for pancreatitis, delivered talk on NICE guideline experience. February 2016.	Specific personal non-financial	Declare and participate
GC 05	None	-	-
GC 06	Will be doing a talk about the scope of this guideline at the Liverpool National Pancreatic Patients Forum – 5 May 2017. Will only mention what is available online.	Specific personal non-financial	Declare and participate
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Ashraf Rasheed (upper GI surgeon)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC 13	None	-	-

Ganesan Baranidharan (pain specialist)

Meeting	Declaration	Classification	Action taken
Initial	My special interest is in Neuromodulation for Pain	Non-specific	Declare and

Meeting	Declaration	Classification	Action taken
application	Management. I am considered an International Key Opinion Leader in this field.	personal non-financial	participate
	Have been on the Advisory Board of various Neuromodulation Companies.	Non-specific personal financial	
	In 2016 I attended a Neuromodulation training weekend with Boston Scientific in Budapest at their cost.	Non-specific personal financial	
	21st April 2015 Lecturing at a GP education meeting sponsored by Grunenthal specifically educating regarding Palexia: fee for the event was £200. Other drugs produced by Grunenthal are Arcoxia(R) Tramacet (R) Versatis (R) Zydol (R) In 2014 I attended 2 Neuromodulation training weekends paid completely by Medtronic both in Europe. On 27th June 2015 I attended a Neuromodulation training weekend with NEVRO Corp in Budapest at their cost.	Specific personal financial – over one year ago	
	International Advisory Board for St Jude Medical and Nevro Corporation. Advisory Board member of a new start-up company Nalu Medical (paid for number of hours' advice). (develop neurostimulation for chronic pain management, not an intervention considered in guideline).	Non-specific personal financial	Declare and participate
	Un Restricted Educational Grant Nevro Corporation – Currently running a study on managing Low back pain using neurostimulation (NHS portfolio study)	Non-specific Non-personal financial	
	St Jude Medical – Have been offered an Educational Grant to do a Pilot RCT on use of Dorsal Root Ganglion Stimulation for managing Pain secondary to Pancreatitis (develop neurostimulation for chronic pain management, not an intervention considered in guideline).	Non-specific Non-Personal financial	
	St Jude Medical and Nevro – Grant for a Research Nurse organised by the Trust (develop neurostimulation for chronic pain management, not an intervention considered in guideline).	Non-specific Non-personal Financial	
Secretary, Neuromodulation Society of the UK and Ireland	Non-specific personal Non-financial		
GC 01	None	-	-
GC 02	None	-	-
GC 03	Dec 2016 - Cadaver Workshop in Barcelona organised by ECMT (http://ecmt-training.com/) Attended as an invited Faculty with Honorarium	Non-specific personal financial	Declare and participate
	Dec 2016 – European Advisory Board for Boston Scientific as a Consultant (Paid Personal)	Non-specific personal financial	Declare and participate
	Nov 2016 – Represented Nevro Corporation as a Clinical Expert (paid Personal) for a Court Hearing on Patent	Non-specific personal non-financial	Declare and participate
GC 04	Had an advisory board meeting on 20th January 2017 at	Specific personal	Declare and

Meeting	Declaration	Classification	Action taken
	North American Neuromodulation Society Meeting, Las Vegas. This is for advice on their development of the neuromodulation device and plans for their clinical study looking at back pain.	non-financial	participate
GC 05	Two day International Executive Advisory Board meeting Abbott (previous St Jude Medical). Financial as per previous declarations – ongoing consultancy agreement. Invited article on abdominal pain by Mundipharma.	Non-Specific personal financial	Declare and participate
GC 06	Conducted a course on Neuromodulation aimed at advanced pain trainees, sponsored by Industry and approved by Royal College of Anaesthetists in March 2017.	Non-specific personal financial	Declare and participate
GC 07	Attended International Neuromodulation Society Meeting in Edinburgh as a Faculty. This waived my registration fee and my stay. Attended International Advisory Board on Peripheral Nerve Stimulation for treating Chronic Pain. This meeting was to advice on development of a new product (30/05/2017). Paid role, not related to Pancreatitis.	Non-specific personal non-financial Non-specific personal financial	Declare and participate
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	Attended user roundtable conference on improving outcomes in Neuromodulation - Sponsored to travel and stay for the meeting in New York as an Expert in Neuromodulation (2 nd December 2017).	Non-specific, personal non-financial	Declare and participate
GC 13	None	-	-

James Shaw (diabetes specialist) – co-opted member

Meeting	Declaration	Classification	Action taken
Initial application	Member of the Medtronic UK Scientific Advisory Board Received travel support from Novo Nordisk to attend and present data at the American Diabetes Association Annual Scientific Sessions, New Orleans, June 2016	Non-specific personal financial Non-specific personal non-financial	Declare and participate
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-

Meeting	Declaration	Classification	Action taken
GC 12	None	-	-
GC 13	None	-	-

Jonathan Booth (non-specialist gastroenterologist)

Meeting	Declaration	Classification	Action taken
Initial application	Annual meeting sponsored by Mylan - they make creon, does not get paid but the company helps to organise the event. Creon is an enzyme replacement therapy	Specific personal non-financial	Declare and participate
	I also own a few shares in Advanced Medical Solutions [advanced wound care, surgical and wound closure] - personal investment choice	Non-specific personal financial	
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	Attended a regional pancreatitis meeting that was sponsored by Mylan. No personal payment received.	Specific personal non-financial	Declare and participate
GC13	None	-	-

Louise Carr (lay member)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Manu Nayar (specialist gastroenterologist)

Meeting	Declaration	Classification	Action taken
Initial application	European Group for Endoscopic Ultrasonography meeting; Edinburgh, October 2015 - 300 euros by Medtronic U.K.	Non-specific Personal financial	Declare and participate
	LEEDS Endoscopic retrograde cholangio-pancreatography (ERCP) MASTERCALSS – JULY 2016 - £1500/- by Olympus U.K. Paid speaking arrangement.	Specific Personal Financial	Declare and withdraw for discussions on Diagnosing Chronic Pancreatitis
GC 01	None	-	-
GC 02	None	-	-
GC 03	Declared during initial interviews: Leeds: ERCP Master class, July 2016, £1500 – by Olympus UK.	Specific personal financial	Declare and withdraw for discussions on Diagnosing Chronic Pancreatitis
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	I was invited faculty for the International ERCP symposium in Stoke on Trent on 28/04/2017. Aquilant UK paid for my travel and accommodation expenses. No personal honorariums received.	Personal non-financial non-specific	Declare and participate
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Mary Phillips (dietitian)

Meeting	Declaration	Classification	Action taken
Initial application	The course I ran in September in Guildford was the same PEI course mentioned below (on pancreatic enzyme replacement therapy). Delivered to a group of 20 Dietitians, as previously there was no attendance by industry, and they have no input into the content of the course. It is funded by an unconditional educational grant that includes an honorarium for the trainer.	Specific Personal Financial	Declare and withdraw for reviews including enzyme replacement therapy
	Mylan Pharmaceuticals I have received honoraria and travel expenses for speaking at educational meetings: The Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland (NIGPS) run a course for Dietitians on the identification and management of pancreatic exocrine insufficiency; this is funded by an	Specific Personal Financial	Declare and withdraw for reviews including enzyme replacement therapy

Meeting	Declaration	Classification	Action taken
	unconditional education grant from Mylan. Mylan have not had any input to the content of the course, and we do not encourage trade-stands at the meetings. For each course I run I submit a budget request to Mylan, and this is paid to NIGPS to allow us to run the course. This includes a honoraria for the speakers. I have run 13 courses to date, and have a financial commitment from Mylan to continue running them over the next 2 years. Mylan produce an enzyme replacement therapy product.		
	I have spoken at various nutrition and dietetic department journal clubs on nutritional management of patients with pancreatic exocrine insufficiency, and received honoraria from Mylan for doing so, Mylan have had no input to the content of my presentation. Mylan produce an enzyme replacement therapy product.	Specific Personal Financial	Declare and withdraw for reviews including enzyme replacement therapy
	Conference attendance sponsorship (registration and accommodation only) for Pancreatic Society Meetings 2015 and 2016 and HPBSurg 2016 (registration, travel and accommodation).	Specific Personal Non financial	Declare and participate
	Site PI on a European commercial trial September 2015-June 2016. This was a non-intervention validation of a patient questionnaire with the aim of developing and validating a screening tool for chronic pancreatitis patients with pancreatic exocrine insufficiency, this trial is completed. My Trust received a payment for each patient recruited (n=10); this was part of a bank contract I hold with the trust, and I did not receive any payment other than my usual hourly rate for the time taken to complete the patient questionnaire.	Non-specific Non-Personal Financial	Declare and participate
	Nutricia Clinical Care Site PI on a commercial multicentre clinical trial on the efficacy of an enteral feed – due to commence October 2016. This is a trial to evaluate a new peptide enteral feeding product licensed for use in patients with intractable malabsorption, with the aim of assessing tolerance of a product compared to other commercially available products. The sample group will be patients already receiving peptide based enteral feeds. We have been asked to recruit 6 patients. The contracts are not yet finalised for this trial, and I am prepared to withdraw if this is deemed a conflict of interest by NICE. Comparison of enteral feeds not an intervention in guideline. Nutricia makes oral feeds too. There is a question comparing oral to enteral feeding.	Specific Non-personal Financial	Declare and participate
	VitaFlo International Honoraria for speaking at an educational event: VitaFlo sponsored a British Dietetic association study day in January 2016 in Birmingham on the management of pancreatic and liver disease. I spoke on the nutritional management of pancreatic disease, and received travel and accommodation reimbursement and an honoraria. VitaFlo did not have any input to the content of my presentation, and I did not include any reference to their	Non-specific Personal Financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	products within the presentation. Vitaflo make oral supplements that could be used for nutrition support in pancreatitis. Not comparing oral supplements in guideline.		
	MERCK I received honoraria for speaking at an Enhanced Recovery Study day funded by MERCK in Guildford in June, and this is being repeated in September 2016. My session is part of a surgical and anaesthetic study day, and my presentation is on the implementation of an enhanced recovery programme in pancreatico-duodenectomy. MERCK have not had any input into the content of my presentation.	Non-specific Personal Financial	Declare and participate
GC 01	No change	-	-
GC 02	Pancreatic exocrine insufficiency (PEI) course taught in Guildford (Sept 2016): Honoraria received. National Course (previously declared) sponsored by an unconditional educational grant from Mylan. Mylan had no input to the content of the course and were not in attendance. Mylan produce an enzyme replacement therapy product.	Specific personal financial	Declare and participate for this meeting. Withdraw for reviews including enzyme replacement therapy discussed at other meetings.
	CECOG (Central European Cooperative Oncology Group) conference in Vienna (12.11.16) – speaking on Pancreatic Cancer and Nutrition. Honoraria, travel and accommodation paid for by conference organiser	Non specific Personal Financial	Declare and participate
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	Honoraria received from Northern Ireland Health Board for presentation at Dietitians education meeting on pancreatic exocrine insufficiency. Honoraria received from Mylan for presenting at Diabetes Nurse Study day (TREND) on pancreatic exocrine insufficiency.	Non-specific personal financial Specific personal financial	Declare and participate Declare and participate for this meeting. Withdraw for reviews including enzyme replacement therapy discussed at other meetings.
GC 09	None		

Meeting	Declaration	Classification	Action taken
GC 10	None	-	-
GC 11	None	-	-
GC 12	Co-authored article: "Nutritional Therapy in Chronic Pancreatitis" for a special issue of Gastroenterology Clinics on Nutritional Management of Gastrointestinal Diseases review on nutrition support in chronic pancreatitis	Specific personal non-financial	Withdraw during discussion of recommendation related to Nutrition in Chronic Pancreatitis.
GC 13	None	-	Withdraw during discussion of recommendation related to Nutrition in Chronic Pancreatitis.

Peter Hampshire (critical care specialist) – co-opted member

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Robert Sutton (pancreatic surgeon)

Meeting	Declaration	Classification	Action taken
Initial application	I have an over-riding, specific interest in the prevention, diagnosis and treatment of acute and chronic pancreatitis. Specifically I am interested in the research development of new and personalised approaches to the management of pancreatitis, to reduce death, to prolong survival and to alleviate human suffering from pancreatitis, over and above what can be achieved through the fullest implementation of optimal guidelines. This is my over-riding professional concern alongside making every endeavour to provide optimal care for all patients with	Specific personal non-financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	<p>pancreatic digestive diseases at a leading regional specialist unit in Liverpool. Institutional research grant income is essential to this objective, guided by the Nolan Principles of Public Life: selflessness, integrity, objectivity, accountability, openness, honesty and leadership. Importantly, there are no drugs available for the treatment of pancreatitis to modify the disease, and much of my research is directed at development of new and/or repositioned drugs to treat the disease. This is to achieve the aims of reducing death, prolonging survival and alleviating human suffering.</p> <p>[PUBLICLY HELD VIEW]</p>		
	<p>I have spent many years unravelling critical mechanisms and encouraging development of new drugs for acute pancreatitis, one of which is intended to enter phase I studies (CalciMedica's CM 4620, safety and pharmacokinetic studies; n.b. CalciMedica do not market any approved product for any disease) within six months, but which will have to go through years of development (phase IIa, then phase IIb and then phase III 'pivotal' regulatory trials) before it might be considered to be clinically applicable; many drugs fail these steps.</p> <p>[RESEARCH]</p>	<p>Non specific Personal Non financial</p>	<p>Declare and participate</p>
	<p>I am the principal investigator on an Efficacy and Mechanism Evaluation (MRC/NIHR) application to conduct a multicentre phase IIb (efficacy not effectiveness) randomised study of infliximab (from Merck/MSD who market this as Remicade®) in acute pancreatitis, that has reached 'intent to fund' status. Infliximab is not used in the treatment of acute pancreatitis, nor are there sufficient data and there is no regulatory approval for the use of infliximab in acute pancreatitis. There is no reason whatsoever for investigation of the potential effects of these drugs to influence the current management of acute pancreatitis, as all these compounds have no current role at all in the treatment of acute pancreatitis. There are no data within the evidence base from which the guidelines are to be compiled for the use of any of these drugs in the management of pancreatitis, and there is no reason to modify any guideline on pancreatitis as a result of the research that I am undertaking on drug discovery and development described above.</p>	<p>Non specific Personal Non financial</p>	<p>Declare and participate</p>
	<p>Other than occasional medicolegal expert witness (I have a current instruction relating to a bile duct injury and undertaken at the request of a senior physician but my last case was over 5 years ago)</p>	<p>Specific non-personal non financial:</p>	<p>Declare and participate</p>
	<p>[Additionally] a small number of holiday lettings on a privately owned property My sole source of income is paid by salary from the University of Liverpool, through my employment as a Professor of Surgery and Honorary Consultant Surgeon.</p> <p>I hold this honorary position at the Royal Liverpool and Broadgreen University Hospitals NHS Trust. I do not undertake private practice.</p>		<p>Declare and participate</p>

Meeting	Declaration	Classification	Action taken
	[EMPLOYMENT/INCOME – NOT RELEVANT TO THE GUIDELINE’S WORK]		
	My principal non-personal financial interest is to secure and develop innovative programmes of research at the University of Liverpool and Royal Liverpool and Broadgreen University Hospitals NHS Trust, endeavouring to maintain the highest ethical standards to advance the management of pancreatitis. Much of this research is preclinical (funded by the Medical Research Council and members of the Association of Medical Research Charities) or early stage translational (proof of principle, funded by the National Institute for Health Research) and has unfortunately yet to achieve late stage translation that would enter the realm of the evidence base that will inform guidelines for the management of pancreatitis. The number and size of the grants are commensurate with what is necessary to have a significant likelihood of reducing death, prolonging survival and/or alleviating human suffering from pancreatitis through research, over and above what can be achieved through the fullest implementation of optimal guidelines from the current evidence base.	Non-specific Financial Non-Personal	Declare and participate
	I am chief/principal/co- investigator on the following research grants awarded to the University of Liverpool and/or Royal Liverpool and Broadgreen University Hospitals NHS Trust that are current or have expired within the last 12 months: The role of IP3 receptors and Orai channels in the physiology and pathophysiology of pancreatic acinar cells (CoI). Liverpool-RIKEN PhD Studentship for David Collier: 1 October 2011 to 30 September 2015: £75,000	Non-specific non-personal Financial	Declare and participate
	(2) Preclinical testing of agents for acute pancreatitis (PI). China Scholarship Council: Research Fellowship for Li Wen: 1 October 2011 to 30 September 2015; £100,000	Non-specific Non-personal Financial	Declare and participate
	(3) Pancreatic Digestive Diseases Biomedical Research Unit (PI). NIHR: BRU Revenue Funding: 1 April 2012 to 31 March 2017: £6,500,000	Non-specific Non personal Financial	Declare and participate
	(4) Chemical synthesis of novel cyclophilin D inhibitors (CoI). EPSRC 50% PhD Studentship for Emma Shore: 1 October 2012 to 30 September 2016: £70,000	Non specific Non personal Financial	Declare and participate
	(5) Interaction of endocytic vacuoles with cellular organelles as a trigger for the cell damage in acute pancreatitis (CoI). MRC Research Grant: 1 April 2013 to 31 March 2016: £509,047	Non specific Non personal Financial	Declare and participate
	(6) Liverpool Imaging Partnership: Molecular physiology and drug response (CoI). MRC Infrastructure Award: 1 April 2013 to 31 March 2017: £1,025,736	Non specific Non personal Financial	Declare and participate
	(7) Liverpool Biomedical Research Centre in Personalised Health (CI). Liverpool Health Partners (non-NIHR): 1 October 2014 to 31 March 2017: £1,500,000 (2014-17)	Non specific Non personal Financial	Declare and participate
	(8) Preclinical drug testing for acute pancreatitis (PI). China Scholarship Council: Research Studentship for	Non Specific Non personal	Declare and participate

Meeting	Declaration	Classification	Action taken
	Stephanie Zhang: 1 October 2014 to 30 September 2018: £100,000	Financial	
	(9) Preclinical development of cyclophilin inhibitors in acute pancreatitis (PI). Cypralis Research Grant: 1 January 2015 to 31 December 2016: £84,000	Non specific Non personal financial	Declare and participate
	(10) TNF alpha signaling in acute pancreatitis (PI): Mersey Deanery: Madel Research Fellowship for Ajay Sud: 1 April 2015 to 31 March 2017: £90,000	Non specific Non personal Financial	Declare and participate
	(11) Neutrophil-acinar cell interactions in acute pancreatitis (PI). Royal College of Surgeons of England: Research Fellowship for Peter Szatmary; 1 August 2015 to 31 July 2016: £50,000	Non specific Non personal Financial	Declare and participate
	(12) Chemical synthesis of novel inhibitors of cyclophilin D (Co-I). EPSRC 50% PhD Studentship for Michael Rogers: 1 October 2015 to 30 September 2019: £70,000	Non specific Non personal Financial	Declare and participate
	(13) The role of the mitochondrial Ca ²⁺ uniporter in initiation and development of acute pancreatitis (Co-I). MRC: Research Grant: 1 April 2016 to 31 March 2019: £403,000	Non specific Non personal Financial	Declare and participate
	(14) NIHR Senior Investigator (PI). NIHR: Investigator Award: 1 April 2016 to 31 March 2012: £450,000 (£375,000 to Research Capability Funding at RLBHUT)	Non specific Non personal Financial	Declare and participate
	(15) TNF alpha signaling in acute pancreatitis (PI). Royal College of Surgeons of England: Research Fellowship for Ajay Sud: 1 April 2017 to 31 March 2018: £50,000	Non specific Non personal financial	Declare and participate
	The University of Liverpool offers a consultancy service by means of which external organisations, public and private, can obtain expert advice from senior academic staff (please see: https://www.liverpool.ac.uk/business/services/research-and-consultancy/). I am registered on this service to provide advice and collaborate to develop new treatments for pancreatitis, including a contract with Cypralis Ltd (http://www.cypralis.com) that begun on 1 August 2016 at £10,000 p.a..	Non specific Non personal Financial	Declare and participate
	Currently the work with Cypralis is entirely preclinical in nature (see also grant 9 above); if there is a promising lead candidate identified, Cypralis intend to undertake a full, regulatory preclinical toxicology work package. If approved by the regulatory bodies (including the Medicines and Healthcare products Regulatory Agency), this will be a prelude to first-in-man phase I studies of single and multiple ascending doses of their chosen compound, again years away from clinical application other than in phase I, phase IIa, phase IIb and phase III clinical trials. This work has no bearing on the evidence base for pancreatitis guidelines, and Cypralis do not market any approved product for the management of any disease.	Non specific Non personal Financial	Declare and participate
	Director, NIHR Liverpool Pancreas Biomedical Research Unit, 2008-2017 Co-opted member of Executive Committee, Pancreatic	Specific personal non-financial:	Declare and participate

Meeting	Declaration	Classification	Action taken
	Society of Great Britain and Ireland (as Chair of Guideline Development Committee; previously member 1998-2001 and 2005-2014, President 2012-2013), 2014 et seq Faculty, American Pancreatic Association, 2004 et seq Member of Council, International Association of Pancreatology, 2008-2016 [MEMBERSHIPS]		
	Director of Research, Development and Innovation, Royal Liverpool and Broadgreen University Hospital NHS Trust, 2009 et seq Director of Research, Liverpool Health Partners, 2013 et seq Research Awards Committee, CORE (Digestive Disorders Foundation), 2003 et seq Member, Association of UK University Hospitals Research Directors, 2011 et seq	Non-specific personal non-financial	Declare and participate
	Previously contributed to editorship within the Cochrane Collaboration as Joint Editor Cochrane Hepatobiliary Collaborative Review Group, 1996-2012; I have also contributed to peer reviewing for public funding organisation and peer-reviewed journals for 30 years.	Non-specific personal non-financial	Declare and participate
	Has published the following original articles in 2015 and 2016: (1) Chvanov M, Huang W, Jin T, Wen L, Armstrong J, Elliot V, Alston B, Burdyga A, Criddle DN, Sutton R, Tepikin AV. Novel lipophilic probe for detecting near-membrane reactive oxygen species responses and its application for studies of pancreatic acinar cells: effects of pyocyanin and L-ornithine. <i>Antioxid Redox Signal</i> 2015; 22: 451-464. (2) Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, Pereira SP, Jacobs I, Cox TF, Greenhalf W, Timms JF, Sutton R, Neoptolemos JP, Costello E. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. <i>J Proteomics</i> 2015; 113: 400-402. (3) Voronina S, Collier D, Chvanov M, Middlehurst B, Beckett AJ, Prior IA, Criddle DN, Begg M, Mikoshiba K, Sutton R, Tepikin AV. The role of Ca ²⁺ influx in endocytic vacuole formation in pancreatic acinar cells. <i>Biochem J</i> 2015; 465: 405-412. (4) Wang YC, Szatmary P, Zhu JQ, Xiong JJ, Huang W, Gomas I, Nunes QM, Sutton R, Liu XB. Prophylactic intra-peritoneal drain placement following pancreaticoduodenectomy: a systematic review and meta-analysis. <i>World J Gastroenterol</i> 2015; 21: 2510-2521. (5) Nicholson JA, Greenhalf W, Jackson R, Cox TF, Butler JV, Hanna T, Harrison S, Grocock CJ, Halloran CM, Howes NR, Raraty MG, Ghaneh P, Johnstone M, Sarkar S, Smart HL, Evans JC, Aithal GP, Sutton R, Neoptolemos JP, Lombard MG. Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal	Non-specific personal non-financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	<p>diclofenac. <i>Pancreas</i> 2015; 44: 260-265.</p> <p>(6) Huang W, Cash N, Wen L, Szatmary P, Mukherjee R, Armstrong J, Chvanov M, Tepikin AV, Murphy MP, Sutton R, Criddle DN. Effects of the mitochondria-targeted antioxidant mitoquinone in murine acute pancreatitis. <i>Mediators Inflamm</i> 2015; 2015:901780.</p> <p>(7) Huang W, Xiong JJ, Wan MH, Szatmary P, Bharucha S, Gomatos I, Nunes QM, Xia Q, Sutton R, Liu XB. Meta-analysis of subtotal stomach-preserving pancreaticoduodenectomy vs pylorus preserving pancreaticoduodenectomy. <i>World J Gastroenterol</i> 2015; 21: 6361-6373.</p> <p>(8) Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Latawiec D, Chvanov M, Collier D, Huang W, Barrett J, Begg M, Stauderman K, Roos J, Grigoryev S, Ramos S, Rogers E, Whitten J, Velicelebi G, Dunn M, Tepikin AV, Criddle DN, Sutton R. Inhibitors of ORAI1 Prevent Cytosolic Calcium-Associated Injury of Human Pancreatic Acinar Cells and Acute Pancreatitis in 3 Mouse Models. <i>Gastroenterology</i> 2015; 149: 481-492.</p> <p>(9) Ou X, Cheng Z, Liu T, Tang Z, Huang W, Szatmary P, Zheng S, Sutton R, Toh CH, Zhang N, Wang G. Circulating histone levels reflect disease severity in animal models of acute pancreatitis. <i>Pancreas</i> 2015; 44: 1089-1095.</p> <p>(10) Gomatos IP, Halloran CM, Ghaneh P, Raraty MG, Polydoros F, Evans JC, Smart HL, Yagati-Satchidanand R, Garry JM, Whelan PA, Hughes FE, Sutton R, Neoptolemos JP. Outcomes from minimal access retroperitoneal and open pancreatic necrosectomy in 394 patients with necrotizing pancreatitis. <i>Ann Surg</i> 2015 Oct 22. [Epub ahead of print]</p> <p>(11) Huang W, Cane MC, Mukherjee R, Szatmary P, Zhang X, Elliott V, Ouyang Y, Chvanov M, Latawiec D, Wen L, Booth D, Haynes AC, Petersen OH, Tepikin AV, Criddle DN, Sutton R. Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca²⁺ release. <i>Gut</i> 2015 Dec 7. [Epub ahead of print]</p> <p>(12) Sultana A, Jackson R, Tim G, Bostock E, Psarelli EE, Cox TF, Sutton R, GhanehP, Raraty MG, Neoptolemos JP, Halloran CM. What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and meta-analyses. <i>Clin Transl Gastroenterol</i> 2015 Dec 10;6:e130. doi:10.1038/ctg.2015.60.</p> <p>(13) Okeke E, Parker T, Dingsdale H, Concannon M, Awais M, Voronina S, Molgo J, Begg M, Metcalf D, Knight AE, Sutton R, Haynes L, Tepikin AV. Epithelial- mesenchymal transition, IP3 receptors and ER-PM junctions: translocation of Ca²⁺ signalling complexes and regulation of migration. <i>Biochem J</i> 2016 Jan 12 [Epub ahead of print]</p> <p>(14) Gomatos IP, Halloran C, Ghaneh P, Raraty M, Polydoros F, Campbell F, Evans J, Sutton R, Garry J, Whelan P, Neoptolemos JP. Management and outcome of 64 patients with pancreatic serous cystic neoplasms. <i>Dig Surg</i> 2016; 33: 203-212.</p>		

Meeting	Declaration	Classification	Action taken
	<p>(15) Shore E, Awais M, Kershaw N, Gibson R, Pandalaneni S, Latawiec D, Wen L, Javed M, Criddle D, Berry N, O'Neill P, Lian L-Y, Sutton R. Small molecule inhibitors of cyclophilin D to protect mitochondrial function as a potential treatment for acute pancreatitis. <i>J Med Chem</i> 2016; 59: 2596-2611.</p> <p>(16) Xiong JJ, Szatmary P, Huang W, Iglesia-Garcia D, Nunes QM, Xia Q, Hu WM, Sutton R, Liu XB, Raraty MG. Enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy: A PRISMA-compliant systematic review and meta-analysis. <i>Medicine</i> 2016; 95: e3497.</p> <p>(17) Mukherjee R, Mareninova OA, Odinkova IV, Huang W, Murphy J, Chvanov M, Javed MA, Wen L, Booth DM, Cane MC, Awais M, Gavillet B, Pruss RM, Schaller S, Molkentin JD, Tepikin AV, Petersen OH, Pandol SJ, Gukovsky I, Criddle DN, Gukovskaya AS, Sutton R; and NIHR Pancreas Biomedical Research Unit. Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. <i>Gut</i> 2016; 65: 1333-1346.</p>		
	Has published the following review articles and book chapters in 2015 and 2016:		
	(1) Awais M, Voronina SG, Sutton R. An efficient method is required to transfect non-dividing cells with genetically encoded optical probes for molecular imaging. <i>Anal Sci</i> 2015; 31: 293-298.	Non-specific personal non-financial	Declare and participate
	(2) Afghani E, Pandol S, Shimosegawa T, Sutton R, Wu B, Vege SS, Gorelick F, Hirota M, Windsor J, Lo SK, Freeman M, Lerch MM, Tsuji Y, Melmed GY, Wassef W, Mayerle J. Acute pancreatitis: progress and challenges. A report on an international symposium. <i>Pancreas</i> 2015; 44: 1195-210.	Specific personal non-financial	Declare and participate
	(3) Cummings M, Bodansky J, Hicks D, Hopkins D, Kirby M, Sutton R. Pancreatic exocrine insufficiency in diabetes: why it is important and what are the practicalities in diagnosis and management. <i>Diabetes Digest</i> 2015; 13 (Suppl 3):2-8.	Non-specific personal non-financial	Declare and participate
	(4) Huang W, Szatmary P, Wan M, Bharucha S, Awais M, Tang W, Criddle DN, Xia Q, Sutton R. Translational insights into peroxisome proliferator-activated receptors in experimental acute pancreatitis. <i>Pancreas</i> 2015 Nov 17. [Epub ahead of print]	Non-specific personal non-financial	Declare and participate
	(5) Wen L, Javed MA, Altaf K, Szatmary P and Sutton R. Specific treatment for acute pancreatitis. In: Adams DB, Cotton PB, Zyromski NJ, Windsor J, eds. <i>Pancreatitis: medical and surgical management</i> . Oxford: Wiley, in press.	Specific personal Non-financial	Declare and participate
	(6) Mukherjee R, Sutton R. Pharmaceutical developments for chronic pancreatitis: pipelines and future options. <i>Pancreapedia: Exocrine Pancreas Knowledge Base</i> , DOI: 10.3998/panc.2016.12.	Non-specific personal financial	Declare and participate
	(7) Wen L, Mukherjee R, Huang W, Sutton R. Calcium	Non-specific	Declare and

Meeting	Declaration	Classification	Action taken
	signaling, mitochondria and acute pancreatitis: avenues for therapy. Pancreapedia: Exocrine Pancreas Knowledge Base, DOI: 10.3998/panc.2016.15.	personal financial	participate
GC 01	None		
GC 02	None	-	-
GC 03	None	-	-
GC 04	International Chair of the West China Pancreas International Forum 15th – 16th October 2016 held at the Ritz Carlton Hotel, Chengdu, China with expenses paid by West China Hospital. Member of the NHS England Hepato-Pancreato-Biliary Clinical Reference Group as representative of the Pancreatic Society of Great Britain and Ireland from 6th October 2016.	Non Specific personal financial	Declare and participate.
GC 05	None	-	-
GC 06	None	-	-
GC 07	None	-	-
GC 08	None	-	-
GC 09	A new grant from Innovate UK (£300,000) with Cypralis PLC on testing molecules that inhibit cyclophilin D for the treatment of chronic pancreatitis (preclinical). 01/08/17 – 31/07/18.	Personal Non specific financial	Declare and participate
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Stacey Munnely (nurse)

Meeting	Declaration	Classification	Action taken
Initial application	I am currently working as part of a project team to develop and launch a virtual internet based clinic for patients with stable chronic pancreatitis to access follow up care in place of their traditional face to face outpatient clinic appointment for my employer (CMFT NHS Trust). The work involves collaborating with a commercial sector IT company who will provide a bespoke computer package which will help clinicians to perform health consultations and assess patients remotely by asking a series of set questions related to symptoms. Decisions regarding further investigations required or changes to treatment will then be made and communicated to the patients and their GPs by the responsible clinician via telephone/letter. The computer package simply allows patients to submit data related to their condition and does not make clinical decisions or replace the clinical expertise/judgement of the reviewing clinician. The aim of the virtual clinic is to use technology to facilitate a new innovative way to access healthcare that is convenient and safe and will free up traditional clinic spaces for new patients, consequently reducing waiting times for new referrals in line with new 2015 British	Non-specific Personal Non-financial	Declare and participate

Meeting	Declaration	Classification	Action taken
	<p>Society of Gastroenterology targets for referral to consultation and improving patient engagement and satisfaction.</p> <p>There will be no personal financial rewards. The Trust will incur a financial recompense from local commissioners in the same way that it does for traditional outpatient clinic appointments.</p> <p>I have made no publications or public statements regarding the project but may do so in the future if the project aims are achieved.</p>		
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	<p>From March 2017, I have been recruited to contribute to and deliver the content of a degree level module for post registration Nurses/Allied Health Care Professionals by the University of Manchester. Topics will include the anatomy, physiology, pathophysiology, management and evidence/research to support management of GI diseases including liver diseases, pancreatic and biliary diseases. I will not receive financial payment for this work.</p>	Specific personal non-financial	Declare and participate.
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Stuart Wood (lay member)

Meeting	Declaration	Classification	Action taken
Initial application	None	-	-
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	None	-	-
GC 05	None	-	-
GC 06	<p>Attended a meeting of the Liverpool Clinical Trial Unit PPI Group on 28th April 2017. The only payment that I received was for travel expenses. I have been invited to join the committee for which I will, on future occasions, receive a fee as well as expenses.</p>	Non-specific personal financial	Declare and participate
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-

Meeting	Declaration	Classification	Action taken
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-
GC13	None	-	-

Tassos Grammatikopoulos (paediatrician)

Meeting	Declaration	Classification	Action taken
Initial application	Children's Liver Disease Foundation research grants in portal hypertension (x2)	Non-specific non-personal financial	Declare and participate
	<p>Papers:</p> <p>Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis.</p> <p>Grammatikopoulos T, Sambrotta M, Strautnieks S, Foskett P, Knisely AS, Wagner B, Deheragoda M, Starling C, Mieli-Vergani G, Smith J; University of Washington Center for Mendelian Genomics, Bull L, Thompson RJ.</p> <p>J Hepatol. 2016 Jul 25. pii: S0168-8278(16)30342-7. doi: 10.1016/j.jhep.2016.07.017. [Epub ahead of print]. PMID: 27469900. Financial support for above work(non-personal). Funding for this project included NIH R01 DK094828 to L.N.B. and R.J.T., the UCSF-King's. College Health Partners Faculty Fellowship Travel Grant (UCSF Academic Senate) to L.N.B., and NIH U01 DK062500 to P. Rosenthal, as well as a gift of funds from A.S. Knisely. WES was undertaken by the University of Washington Center for Mendelian. Genomics (UW CMG) and was funded by the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute grant 1U54HG006493 to Drs. Debbie Nickerson, Jay Shendure, and Michael Bamshad.</p>	Non-specific Personal Non-financial	Declare and participate
GC 01	None	-	-
GC 02	None	-	-
GC 03	None	-	-
GC 04	Travel sponsored by Nutricia for lecturing on neonatal cholestasis in December 2016.	Non-specific personal financial	Declare and Participate
GC 05	None	-	-
GC 06	The department was sponsored for organising an international symposium in paediatric liver transplantation at King's College Hospital, London by the International Liver Transplantation Society and pharmaceutical companies Alexion, Intercept and Gilead. I was the symposium organiser.	Non-specific non-personal financial	Declare and participate.
GC 07	None	-	-
GC 08	None	-	-
GC 09	None	-	-
GC 10	None	-	-
GC 11	None	-	-
GC 12	None	-	-

Meeting	Declaration	Classification	Action taken
GC13	None	-	-